Ochre Bio is a biotechnology company dedicated to developing RNA-based therapies for chronic liver diseases, aiming to eliminate the necessity for liver transplants. By integrating advanced genomics, artificial intelligence, and experimental biology, Ochre Bio focuses on creating treatments that regenerate diseased livers and enhance donor liver viability.
Key Features and Functionality:
- Human Discovery Platform: Ochre Bio has invested over $20 million to build comprehensive human liver datasets. By integrating proprietary gene perturbation atlases with patient disease atlases, the company makes causal predictions about new drug targets.
- Human Validation Platform: Combining AI with human validation models such as perfused livers, diseased tissue slices, and primary cells, Ochre Bio models biological complexity at scale.
- RNA Platform: The company produces its own RNA therapies in-house, reducing R&D cycle times from years to weeks. This strong RNA modality focus is believed to improve chances of clinical success.
Primary Value and User Solutions:
Ochre Bio addresses the critical shortage of viable donor livers by developing therapies that rejuvenate fatty donor livers before transplantation, thereby increasing the pool of transplantable organs. Additionally, their treatments aim to regenerate diseased livers in patients, potentially reducing or eliminating the need for transplants. This approach offers hope to the 1.5 million people globally who die from liver disease annually, providing innovative solutions to a pressing medical challenge.
